CD44 and neoplasm: As a primary ligand of CD44, HA increases the stability and safety of rGO by enhancing the tumor-targeted distribution of DOX to CD44-overexpressing cancer cells, thereby providing better drug accumulation and substantial reduction of tumor volume from in vivo study in nude mice.